We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Offload Fresenius Medical Stock Now
Read MoreHide Full Article
Fresenius Medical Care (FMS - Free Report) has had a dismal run on the bourses of late. Over the last three months, the company has added 4.4%, underperforming the broader industry’s gain of 5.2%. The current level is also lower than the S&P 500’s return of 5.5%. A rapidly changing healthcare environment in the United States, a sluggish third quarter, tough regulatory environment, difficulties in collecting trade receivables in foreign legal paradigms and competition in the niche markets have been posing significant challenges to the company. The stock has a Zacks Rank #4 (Sell).
Here we take a sneak peek at the major issues plaguing Fresenius at the moment:
Q3 Debacle
Fresenius ended the third quarter on a dismal note, missing the Zacks Consensus Estimate on both the counts. The misses were led by lackluster performance of the renal pharmaceutical segment, which primarily marred Latin-American revenues. We note that the Health Care Services segment at the region declined 1% year over year.
Stiff Competition
Fresenius has a number of competitors in the field of health care services as well as dialysis products. Tough competition from MedTech majors like DaVita Inc. (DVA - Free Report) is likely to impede the company’s sales opportunities and dent market share.
Unfavorable Regulatory Environment
Fresenius has a solid hold in the markets of North America, Europe, Asia Pacific and Latin America. Thus, the company faces the brunt of stringent regulations in almost every country in which it operates. Furthermore, Fresenius has to fulfill specific legal requirements that include tough antitrust regulations. Violating healthcare or other regulations under public law can result in serious legal repercussions.
Fresenius Medical Care Corporation Price and Consensus
Overall, the estimate revision trend for Fresenius has been declining. For the current quarter, one analyst moved south compared to no movement in the opposite direction over the last two months. For the full year, two analysts moved down compared to no upward movement. As a result, the Zacks Consensus Estimate for current-quarter earnings declined by 3.2% to 61 cents. Full-year earnings estimates dropped 1.3% to $2.36 per share.
However, acquisitions have been a key catalyst for the company. In an initiative to boost its long-term strategy or the ‘Growth-Strategy 2020’, Fresenius Medical Care recently signed an agreement to acquire all outstanding shares of NxStage Medical for $30 a share.
The company has a long-term expected earnings growth rate of 10%.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Here's Why You Should Offload Fresenius Medical Stock Now
Fresenius Medical Care (FMS - Free Report) has had a dismal run on the bourses of late. Over the last three months, the company has added 4.4%, underperforming the broader industry’s gain of 5.2%. The current level is also lower than the S&P 500’s return of 5.5%. A rapidly changing healthcare environment in the United States, a sluggish third quarter, tough regulatory environment, difficulties in collecting trade receivables in foreign legal paradigms and competition in the niche markets have been posing significant challenges to the company. The stock has a Zacks Rank #4 (Sell).
Here we take a sneak peek at the major issues plaguing Fresenius at the moment:
Q3 Debacle
Fresenius ended the third quarter on a dismal note, missing the Zacks Consensus Estimate on both the counts. The misses were led by lackluster performance of the renal pharmaceutical segment, which primarily marred Latin-American revenues. We note that the Health Care Services segment at the region declined 1% year over year.
Stiff Competition
Fresenius has a number of competitors in the field of health care services as well as dialysis products. Tough competition from MedTech majors like DaVita Inc. (DVA - Free Report) is likely to impede the company’s sales opportunities and dent market share.
Unfavorable Regulatory Environment
Fresenius has a solid hold in the markets of North America, Europe, Asia Pacific and Latin America. Thus, the company faces the brunt of stringent regulations in almost every country in which it operates. Furthermore, Fresenius has to fulfill specific legal requirements that include tough antitrust regulations. Violating healthcare or other regulations under public law can result in serious legal repercussions.
Fresenius Medical Care Corporation Price and Consensus
Fresenius Medical Care Corporation Price and Consensus | Fresenius Medical Care Corporation Quote
Overall, the estimate revision trend for Fresenius has been declining. For the current quarter, one analyst moved south compared to no movement in the opposite direction over the last two months. For the full year, two analysts moved down compared to no upward movement. As a result, the Zacks Consensus Estimate for current-quarter earnings declined by 3.2% to 61 cents. Full-year earnings estimates dropped 1.3% to $2.36 per share.
However, acquisitions have been a key catalyst for the company. In an initiative to boost its long-term strategy or the ‘Growth-Strategy 2020’, Fresenius Medical Care recently signed an agreement to acquire all outstanding shares of NxStage Medical for $30 a share.
Meanwhile, a better-ranked stock in the broader medical sector is PetMed Express (PETS - Free Report) , with a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The company has a long-term expected earnings growth rate of 10%.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>